Vimarsana
Biggest News Aggregation in the World

Page 17 - Query Get News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Query Get. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Query Get Today - Breaking & Trending Today

Experts debate obesity vs. glycemic control as primary target for treating type 2 diabetes - Vimarsana News

Experts debate obesity vs. glycemic control as primary target for treating type 2 diabetes

NEW ORLEANS — There is no single answer when it comes to determining the primary target for treating type 2 diabetes, two speakers said during a debate at the American Diabetes Association Scientific Sessions. Promoting weight loss to improve health outcomes for people with type 2 diabetes is one of the targets emphasized in the 2022 ADA Standard of Care. Ildiko Lingvay, MD, MPH, MSCS,

Source: healio.com
Abbott restarts production of infant formulas at Michigan plant - Vimarsana News

Abbott restarts production of infant formulas at Michigan plant

Abbott Nutrition restarted production of infant formulas at a Michigan plant that was shut down for months after the company initiated a recall of its powder formulas, beginning the country’s ongoing formula shortage.

Source: healio.com
Food allergy associated with lower SARS-CoV-2 infection risk - Vimarsana News

Food allergy associated with lower SARS-CoV-2 infection risk

People with food allergies showed lower risk for SARS-CoV-2 infection, whereas those with obesity had a higher risk, according to a study published in The Journal of Allergy and Clinical Immunology. Additionally, results of the perspective surveillance study showed asthma did not positively or negatively impact risk for SARS-CoV-2 infection.

Source: healio.com
Dostarlimab shows efficacy as curative-intent treatment in rectal cancer subset - Vimarsana News

Dostarlimab shows efficacy as curative-intent treatment in rectal cancer subset

CHICAGO — Dostarlimab, an anti-PD-1 monoclonal antibody, demonstrated a 100% clinical complete response rate among a small cohort of patients with mismatch repair-deficient locally advanced rectal cancer, phase 2 study results showed.Longer follow-up is needed to examine the duration of treatment response in this patient population, according to researchers of the study, reported at ASCO

Source: healio.com
Q&A: Pegloticase sustained lower serum urate in kidney transplant recipients with gout - Vimarsana News

Q&A: Pegloticase sustained lower serum urate in kidney transplant recipients with gout

Among kidney transplant recipients with uncontrolled gout, pegloticase showed sustained decreased serum urate levels, according to findings presented at the American Transplant Congress.Patients also showed pain relief and decreased disability without worsening kidney function.

Source: healio.com